Ubsetf Asrgba (UC46) Quote

As much as I would like to agree with you, you have to admit that Linda & Reggie are sluggish at best. There is an element of development/growth that has been elusive. Maybe a true plan manager should be considered. Selling the company might also come into the consideration mix. 

Penumbra price target raised to $222 from $205 at RBC Capital
RBC Capital analyst Shagun Singh raised the firm's price target on Penumbra to $222 from $205 and keeps an Outperform rating on the shares as part of a broader research note previewing Q3 results. The firm's industry checks suggest

gooooooooood morning

$USAU is moving upward on the NASDAQ! 📈 The bullish trend is clear—this could be a chance for solid returns.

Oh for sure which is why I've stuck with this one even though I'm down around 60% overall right now with my cost basis. Once those results hit I am hopeful the market will react accordingly and it will ultimately have been a good play to hold and continue accumulating as I can through the dip. I've

NMHI.......BPTH........LAZR.......ONCY........https://stockcharts.com/h-sc/ui?s=NMHI&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=ONCY&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=BPTH&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://

Agree 110%. Just like the bankruptcy garbafe that the pref holders were pushing, all fake nonsense. I believe the capital rule will be reduced, that is the key. Once they announce that, there will be rapid fire release plans and announcements that will follow that. Trump says he has people looki

10-08 S BURU .69 + 18.96% pre

thanks for doing that. I liked the "The Company is actively exploring legal options " part ! Will watch closely for a quick trade, but not getting in above $4,what you think?Wait for a dip?

Finally, they said what is obvious about CNS to most of us..., but, .....hard to do.

"When the strength of a clinical endpoint lies in its design, challenges arise when measures are chosen simply because they are the best available options. As much of a trial’s success depends on the

Already happened on October 3rd

otrk..........viri.........flgc........srfm...................................https://stockcharts.com/h-sc/ui?s=SRFM&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=OTRK&p=D&yr=0&mn=2&dy=12&id=p84071410134
https://stockcharts.com/h-sc/ui?s=VIRI&p=D&yr=0&mn=2&dy=12

James. Possible merger/ buyout candidate ??

Wow, that doesn't sound good. I hope the best for you, stay safe. You can't evacuate ?

Except when both primary endpoints are not met. I guess he forgot that one...

>>>Now quote me and break it down because you’re the best analyst we’ve ever had on this board.

That is funny...haha

Continued:

During an MAA review, it is common for regulators to request additional information regarding outstanding clinical trials, including those that test combinations with the product. Regulators are keen to assess the overall safety and efficacy profile of a product, and any on

I've heard it started in the 60's

First 2 patients from Phase1/2 would have been cured by now… this look like someone at the hospital bought a ton of shares before the world gets the info.

Y’all’s hero Hoffman is on Twitter saying MHRA approval in 2025.

I still kinda think November is in play, but that’s worth listening to. We know the company goes through him to prep social media on timelines. Think there is probably something to his January prediction.

TICK....TOCK....

Laser Photonics Provides Shareholder Update
ORLANDO, Fla.--(BUSINESS WIRE)-- Laser Photonics Corporation (LPC) (NASDAQ: LASE), a leading global developer of industrial laser systems for cleaning and other material processing applications, today commented on recent business updates and trading

Next Wednesday purchasing more NVDA, with my social security check(the wife and I live comfortably on my pension from the University). Foxconn & Super Micro reported more demand/for NVDA chips.💰